KWOK KIN contact WONG

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 67:11924-32. 2007
  2. pmc Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
    Takeshi Shimamura
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Res 68:5827-38. 2008
  3. pmc NF-kappaB fans the flames of lung carcinogenesis
    KWOK KIN WONG
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 3:403-5. 2010
  4. doi request reprint A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
    Kwok K Wong
    Dana Farber Cancer Institute, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:2552-8. 2009
  5. ncbi request reprint HKI-272 in non small cell lung cancer
    KWOK KIN WONG
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:s4593-6. 2007
  6. doi request reprint Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors
    KWOK KIN WONG
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lung Cancer 60:S10-8. 2008
  7. ncbi request reprint Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
    Clin Cancer Res 13:s4583-8. 2007
  8. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  9. ncbi request reprint Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
    Takeshi Shimamura
    Department of Medical Oncology and Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 66:6487-91. 2006
  10. pmc Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:7817-22. 2006

Detail Information

Publications33

  1. ncbi request reprint PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 67:11924-32. 2007
    ..These preclinical evaluations support further clinical development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members...
  2. pmc Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
    Takeshi Shimamura
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Res 68:5827-38. 2008
    ..Nonetheless, these findings suggest that Hsp90 inhibitors may be effective in T790M-expressing cells and offer an alternative therapeutic strategy for this subset of lung cancers...
  3. pmc NF-kappaB fans the flames of lung carcinogenesis
    KWOK KIN WONG
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 3:403-5. 2010
    ..Our growing understanding of the tumor-promoting NF-kappaB downstream effector pathways could lead to the development of novel approaches for lung cancer therapy and chemoprevention...
  4. doi request reprint A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
    Kwok K Wong
    Dana Farber Cancer Institute, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:2552-8. 2009
    ..The dose-limiting toxicities, maximum tolerated dose, pharmacokinetic profile, and preliminary antitumor activity of neratinib (HKI-272), an irreversible pan ErbB inhibitor, were determined in patients with advanced solid tumors...
  5. ncbi request reprint HKI-272 in non small cell lung cancer
    KWOK KIN WONG
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:s4593-6. 2007
    ..A phase II trial of HKI-272 in non-small cell lung cancer patients has been initiated. HKI-272 might offer benefits to non-small cell lung cancer patients who have relapsed after an initial response to erlotinib...
  6. doi request reprint Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors
    KWOK KIN WONG
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lung Cancer 60:S10-8. 2008
    ..Such information may result in the design of highly specific agents that target specific mutations, which could result in more efficacious treatments...
  7. ncbi request reprint Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
    Clin Cancer Res 13:s4583-8. 2007
    ....
  8. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  9. ncbi request reprint Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
    Takeshi Shimamura
    Department of Medical Oncology and Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 66:6487-91. 2006
    ..Thus, the subset of NSCLC patients with tumors carrying the ERBB2 G776insV_G/C mutation may benefit from treatment with HKI-272...
  10. pmc Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:7817-22. 2006
    ..These findings suggest a therapeutic strategy for cancers harboring the EGFRvIII mutation...
  11. ncbi request reprint Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging
    Naomi M Simon
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Biol Psychiatry 60:432-5. 2006
    ..We propose that chronic stress associated with mood disorders may contribute to excess vulnerability for diseases of aging such as cardiovascular disease and possibly some cancers through accelerated organismal aging...
  12. ncbi request reprint Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion
    Jing Deng
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 67:11867-75. 2007
    ..This finding has clear implications for overcoming resistance to erlotinib. Resistance to EGFR inhibition can be modulated by alterations in the intrinsic apoptotic pathway controlled by the BCL-2 family of proteins...
  13. pmc Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment
    Xiangzhi Zhou
    Department of Radiology, Brigham and Women s Hospital, Boston MA, USA
    Comp Med 58:276-81. 2008
    ..The MRI approaches in this work can be applied on other antitumor drug treatment evaluation in vivo when appropriate sequences are chosen...
  14. ncbi request reprint Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
    Yuki Yuza
    Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Biol Ther 6:661-7. 2007
    ..More broadly, these results imply that the development and deployment of targeted therapies should focus on inhibition of specific cancer-causing mutations, not only on the mutated target...
  15. ncbi request reprint The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 9:485-95. 2006
    ..These data suggest that persistent EGFR signaling is required for tumor maintenance in human lung adenocarcinomas expressing EGFR mutants...
  16. ncbi request reprint EGFR targeted therapy: view from biological standpoint
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cell Cycle 5:2072-6. 2006
    ....
  17. ncbi request reprint Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
    Danan Li
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 12:81-93. 2007
    ..However, the combination of HKI-272 and rapamycin resulted in significant regression of both types of lung tumors. This combination therapy may potentially benefit lung cancer patients with the EGFR T790M mutation...
  18. pmc High-resolution genomic profiles of human lung cancer
    Giovanni Tonon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 102:9625-30. 2005
    ..Integrated DNA-RNA analyses identified WHSC1L1 and TPX2 as two candidates likely targeted for amplification in both pancreatic ductal adenocarcinoma and non-small-cell lung cancer...
  19. doi request reprint Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer
    Samanthi A Perera
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Carcinogenesis 29:747-53. 2008
    ..Furthermore, these findings clearly demonstrate (in an in vivo model system) the dual nature of telomere shortening as both a tumor-suppressive and tumor-promoting mechanism in lung cancer, dependent on p53 status...
  20. ncbi request reprint Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing
    KWOK KIN WONG
    Department of Adult Oncology, Dana Farber Cancer Institute Boston, Massachusetts 02115, USA
    Nature 421:643-8. 2003
    ....
  21. ncbi request reprint LKB1 modulates lung cancer differentiation and metastasis
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 448:807-10. 2007
    ..These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis...
  22. pmc Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas
    Danan Li
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 117:346-52. 2007
    ..Taken together, these data support the hypothesis that mAb806 may lead to significant advancements in the treatment of the population of NSCLC patients with these 2 classes of EGFR mutations...
  23. ncbi request reprint Mouse models of lung cancer
    Amit Dutt
    Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:4396s-4402s. 2006
    ..We present here a brief overview of the existing mouse models of lung cancers and the challenges and opportunities for building the next generation of lung cancer mouse models...
  24. ncbi request reprint The age of cancer: telomeres, checkpoints, and longevity
    Ronald A Depinho
    Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 111:S9-14. 2003
  25. pmc DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse
    Richard S Maser
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Mol Cell Biol 27:2253-65. 2007
    ....
  26. ncbi request reprint BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models
    David C Christiani
    Harvard University Schools of Medicine and Public Health, Boston, MA, USA
    J Thorac Oncol 1:S2-7. 2006
    ..However, because BAC appears to behave clinically differently from adenocarcinoma, a better understanding of this disease entity is imperative...
  27. pmc The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
    Cai Hong Yun
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:2070-5. 2008
    ....
  28. ncbi request reprint Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 67:4933-9. 2007
    ..These results unveil a potential common vulnerability of BRAF and KRas mutant lung tumors that potentially affects rational deployment of MEK targeted therapies to non-small-cell lung cancer patients...
  29. pmc Alu elements mediate MYB gene tandem duplication in human T-ALL
    Jennifer O'Neil
    Department of Pediatric Oncology, Belfer Foundation Institute for Innovative Cancer Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Exp Med 204:3059-66. 2007
    ..We conclude that Alu-mediated MYB tandem duplication occurs at low frequency during normal thymocyte development and is clonally selected during the molecular pathogenesis of human T-ALL...
  30. ncbi request reprint Walking the telomere plank into cancer
    KWOK KIN WONG
    J Natl Cancer Inst 95:1184-6. 2003
  31. ncbi request reprint An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
    Cancer Res 65:7096-101. 2005
    ..These data also support the notion that clinical investigations of compounds similar to CL-387,785 may be useful as a treatment strategy for patients with resistance to EGFR inhibitor therapy caused by the T790M mutation...
  32. ncbi request reprint Chromosomal end fusion resulting from telomere erosion increases susceptibility to radiation via multinucleation: effect of p53
    Yeun Jin Ju
    Laboratory of Molecular Oncology, Korea Institute of Radiological and Medical Sciences, Seoul 139 706, Korea
    Int J Oncol 29:753-63. 2006
    ..Thus, the suggested anticancer radiotherapeutic strategy combined with telomerase inhibition could clinically be applicable to cancers, irrespective of p53 status...
  33. pmc Differential roles of telomere attrition in type I and II endometrial carcinogenesis
    Esra A Akbay
    Department of Pathology, UT Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390 9072, USA
    Am J Pathol 173:536-44. 2008
    ..Based on this and previous studies, we propose a model in which telomere attrition contributes to the initiation of TII and progression of TI endometrial cancers...

Research Grants12

  1. Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer
    KWOK KIN contact WONG; Fiscal Year: 2010
    ..Results from the experiments proposed will help guide the clinical development of these combination therapies for patients with lung cancers and other cancer types. ..
  2. EGFRvIII Mutation in Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors
    KWOK KIN WONG; Fiscal Year: 2010
    ....
  3. Dysfunctional Telomeres, Checkpoints and Aging
    KWOK KIN WONG; Fiscal Year: 2007
    ....
  4. EGFRvIII Mutation in Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors
    KWOK KIN WONG; Fiscal Year: 2007
    ....
  5. Dysfunctional Telomeres, Checkpoints and Aging
    KWOK KIN WONG; Fiscal Year: 2010
    ....